Compare HQ & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HQ | DNA |
|---|---|---|
| Founded | 2018 | 2008 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 879.7M | 835.7M |
| IPO Year | 2025 | 2020 |
| Metric | HQ | DNA |
|---|---|---|
| Price | $16.08 | $11.77 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 2 | 3 |
| Target Price | ★ $20.50 | $7.00 |
| AVG Volume (30 Days) | 440.5K | ★ 3.3M |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 46.49 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $170,155,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $13.37 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.29 | $5.37 |
| 52 Week High | $45.00 | $18.22 |
| Indicator | HQ | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 51.95 | 56.18 |
| Support Level | $13.68 | $6.75 |
| Resistance Level | $16.37 | N/A |
| Average True Range (ATR) | 1.22 | 1.72 |
| MACD | 0.18 | 0.03 |
| Stochastic Oscillator | 57.54 | 33.74 |
Horizon Quantum Holdings Ltd is building software infrastructure to make quantum computers accessible to commercial enterprises and hardware providers. By bridging the gap between hardware and applications, the company seeks to equip developers, researchers, and enterprises with the quantum software infrastructure needed to solve real-world problems. The company is developing tools that can automatically accelerate code written for conventional computers on quantum computers.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.